Key Points - Revenue rose 3.0 % year over year to $10.85 billion, surpassing analyst expectations.- Non-GAAP earnings per ...

Shares of the medical equipment maker were up 2.5% in premarket trading. The company joins peers such as Danaher in beating ...

Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday reported second-quarter 2025 adjusted earnings of $5.36 per share, ...

Casper claimed that during the quarter, Thermo Fisher advanced its growth strategy, launching a range of high-impact ...

Thermo Fisher will expand use of the Sanofi site to meet the demand from pharma and biotech customers for U.S. manufacturing capacity.

Q2 2025 Management View CEO Marc N. Casper highlighted "excellent operational performance in the quarter, reflecting active management of our company and the strength of our proven growth strategy and ...

Thermo Fisher is acquiring Sanofi’s Ridgefield, NJ sterile drug plant, transferring 200 employees to bolster U.S. fill‑finish ...

While midazolam is the only sedative labeled for continuous use during mechanical ventilation in pediatric ICU patients, ...

Biogen will invest an extra $2 billion to expand its RTP facilities, focusing on AI-driven manufacturing and late-stage ...

Thermo Fisher Scientific's second quarter of 2025 demonstrated a 3% revenue increase to $10.85 billion, slightly surpassing expectations.

With an aim to enable additional U.S. drug product manufacturing, Thermo Fisher Scientific and Sanofi have decided to expand their strategic partnership. Under the terms of the agreement, Thermo ...

Pharma prepares for looming tariffs, as the US president signals a phased increase starting Aug. 1, but the official starting ...